title: A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy.
abstract: The subset of metastatic colorectal adenocarcinomas that harbor BRAF V600E mutations are aggressive tumors with significantly shortened survival and limited treatment options. Here we present a colorectal cancer patient whose disease progressed through standard chemotherapy and who developed liver metastasis. Comprehensive genomic profiling (FoundationOne(®)) identified a BRAF V600E mutation in the liver lesion, as well as other genomic alterations consistent with colorectal cancers. Combination therapy of dabrafenib and trametinib with standard cytotoxic chemotherapy resulted in a durable major ongoing response for the patient. This report illustrates the utility of comprehensive genomic profiling with personalized targeted therapy for aggressive metastatic colorectal adenocarcinomas.
authors.affiliation: Avera Cancer Institute, Sioux Falls, SD, USA.
authors.forename: Casey B
authors.initials: CB
authors.lastname: Williams
authors.affiliation: Foundation Medicine, Inc., Cambridge, MA, USA.
authors.forename: Caitlin
authors.initials: C
authors.lastname: McMahon
authors.affiliation: Foundation Medicine, Inc., Cambridge, MA, USA.
authors.forename: Siraj M
authors.initials: SM
authors.lastname: Ali
authors.affiliation: Avera Cancer Institute, Sioux Falls, SD, USA.
authors.forename: Mark
authors.initials: M
authors.lastname: Abramovitz
authors.affiliation: Avera Cancer Institute, Sioux Falls, SD, USA.
authors.forename: Kirstin A
authors.initials: KA
authors.lastname: Williams
authors.affiliation: Avera Cancer Institute, Sioux Falls, SD, USA.
authors.forename: Jessica
authors.initials: J
authors.lastname: Klein
authors.affiliation: Avera Cancer Institute, Sioux Falls, SD, USA.
authors.forename: Heidi
authors.initials: H
authors.lastname: McKean
authors.affiliation: Foundation Medicine, Inc., Cambridge, MA, USA.
authors.forename: Roman
authors.initials: R
authors.lastname: Yelensky
authors.affiliation: University of Florida College of Medicine, Gainesville, FL, USA.
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: George
authors.affiliation: Foundation Medicine, Inc., Cambridge, MA, USA.
authors.forename: Julia A
authors.initials: JA
authors.lastname: Elvin
authors.affiliation: Beth Israel Deaconess Medical Center, Boston, MA, USA.
authors.forename: Salil
authors.initials: S
authors.lastname: Soman
authors.affiliation: Foundation Medicine, Inc., Cambridge, MA, USA.
authors.forename: Doron
authors.initials: D
authors.lastname: Lipson
authors.affiliation: Foundation Medicine, Inc., Cambridge, MA, USA.
authors.forename: Juliann
authors.initials: J
authors.lastname: Chmielecki
authors.affiliation: Foundation Medicine, Inc., Cambridge, MA, USA.
authors.forename: Deborah
authors.initials: D
authors.lastname: Morosini
authors.affiliation: Foundation Medicine, Inc., Cambridge, MA, USA.
authors.forename: Vincent A
authors.initials: VA
authors.lastname: Miller
authors.affiliation: Foundation Medicine, Inc., Cambridge, MA, USA.
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Stephens
authors.affiliation: Foundation Medicine, Inc., Cambridge, MA, USA ; Albany Medical College, Albany, NY, USA.
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Ross
authors.affiliation: Avera Cancer Institute, Sioux Falls, SD, USA.
authors.forename: Brian
authors.initials: B
authors.lastname: Leyland-Jones
keywords: BRAF mutations; colorectal adenocarcinoma; combination targeted therapy; oxaliplatin